Landscape Capital Management L.L.C. Invests $2.09 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Landscape Capital Management L.L.C. bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 2nd quarter, HoldingsChannel reports. The fund bought 25,623 shares of the biotechnology company’s stock, valued at approximately $2,089,000.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC raised its stake in shares of Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares during the last quarter. Tsfg LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $25,000. Optiver Holding B.V. boosted its holdings in shares of Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares during the period. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth about $39,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ARWR. Stifel Nicolaus assumed coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They set a “buy” rating and a $98.00 price target on the stock. Royal Bank Of Canada increased their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, August 17th. Morgan Stanley lifted their price objective on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, Chardan Capital boosted their target price on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.33.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael S. Perry sold 11,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the transaction, the director owned 111,459 shares in the company, valued at $9,730,370.70. This trade represents a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 0.4%

NASDAQ:ARWR opened at $87.11 on Friday. The company has a 50-day moving average price of $82.84 and a 200-day moving average price of $72.87. The stock has a market cap of $12.27 billion, a price-to-earnings ratio of -38.72 and a beta of 1.27. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $20.44 and a 12 month high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. During the same quarter in the prior year, the firm earned ($1.26) EPS. Arrowhead Pharmaceuticals’s quarterly revenue was up 171.0% compared to the same quarter last year. Equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.